Goldman Sachs Upgrades PT On Myriad Genetics To $19, Maintains Sell (MYGN)

Goldman Sachs upgraded its prices target on Myriad Genetics (NASDAQ: MYGN) in a research report published today.

Goldman also upgraded its earnings per share forecast, after better than expected Q1 results, but reiterated its Sell rating on Myriad.

In the report, Goldman states, "MYGN reported revenues/EPS of $102mn/$0.31 vs. our $99mn/$0.26 estimate and Street $98mn/$0.25. BRCAnalysis sales of $90.3mn were ahead of our $87.5mn estimate, COLARIS sales were $7.4mn (GS: $6.9mn) and other sales totaled $4.7mn, slightly above our $4.4mn estimate. Management raised FY2011 guidance to $396 – 402mn/$1.06 – 1.09 from $380 – 400mn/$0.95 – 1.00 in EPS partially from the inclusion of Rules Based Medicine related revenues (~$2mn expected). In addition, MYGN provided greater detail on its proposed acquisition of Rules Based Medicine and its go to market strategy in Europe. We revise our FY2011-2013 estimates to $1.08, 1.28, 1.45 from $1.02, 1.19, and 1.36 and raise our price target to $19 from $17."

Myriad's shares added 5.72% to their value today to stand at $22.56.